First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than one hundred million people since the beginning of the worldwide pandemic. In this study, data from a large hospital in central Italy was used to evaluate the impact of the first dose of the BNT162b2 mRNA vaccine on S...

Descripción completa

Detalles Bibliográficos
Autores principales: Coppeta, Luca, Balbi, Ottavia, Grattagliano, Zaira, Mina, Grazia Genga, Pietroiusti, Antonio, Magrini, Andrea, Bolcato, Matteo, Trabucco Aurilio, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234325/
https://www.ncbi.nlm.nih.gov/pubmed/34204252
http://dx.doi.org/10.3390/vaccines9060659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234325/
https://www.ncbi.nlm.nih.gov/pubmed/34204252
http://dx.doi.org/10.3390/vaccines9060659

Ejemplares similares